Regeneron Pharmaceuticals, Inc. (REGN) – A Diversified Growth Story

REGEN-COV continues to grow in importance with increased utilization in the treatment of COVID-19. The FDA has accepted under priority review biologic license application for the treatment and prophylaxis of COVID-19 in certain patients.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 38